MAP2K7 and esophageal squamous cell carcinoma: Additionally, pretreatment with MEK inhibitor (selumetinib) and GSK3β inhibitor (BIO) completely abrogated inhibitory role of melatonin on cell migration in Eca109 and KYSE150 cells, while either agent alone was not enough to attenuate anti-migration activity of melatonin (Figure 3c), further indicating that dual-inhibition of pErk and pAkt was involved in anti-neoplastic role of melatonin in ESCC.